Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India

Boehringer IngelheimBoehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world. Many diseases are spread by not washing hands, as a result of lack of knowledge, very limited access to hygiene products, awareness and missing access to clean water: According to UNICEF, diarrhea remains the second largest cause of mortality for children aged under-five globally. Every year, 1.4 million children die from diarrheal diseases due to a lack of safe water, bad sanitation and basic hygiene.

The Boehringer Ingelheim initiative called ‘Elephants’ was launched end of September 2018 in Coimbatore within the Indian state of Tamil Nadu with a training course for 60 village inhabitants on soap production. The objective is to enable a healthier living in the villages and creating simultaneously an income source for the communities by self-managed soap micro-enterprises. Additionally, the project aims to create business knowledge and logistics skills amongst the participants so that they will be able to independently market their homemade soaps in future. Another core task of this initiative is to increase awareness of infections with communicable diseases due to bad hygiene. The 'Elephants' project is run by Boehringer Ingelheim employees who volunteered to engage in company-sponsored projects in India through the company's initiative Making More Health.

"We know from the western world that there is no health without wealth. This experience seems unknown, unmet or unsolved in our project area. In order to solve this problem we have to combine health with solutions that create an income," explains Manolis Mitakis, Pharmacist and Head of Communications & Public Affairs of the Greek subsidiary of Boehringer Ingelheim, who travelled to India, involved in the Making More Health Executive in Residence Program.

The Boehringer Ingelheim long-term and global initiative Making More Health (MMH) aims to create a healthier world for individuals, communities and families. By supporting social entrepreneurs and social entrepreneurial thinking, MMH is looking for innovative solutions, which create social impact. Together with the local partner-NGO, the Karl Kübel Institute for Development Education and the German federal state Hessen toilets are built or renovated to increase hygiene among schoolchildren in the chosen territory in Tamil Nadu/ India. Education and awareness programs on hygiene help a lot that children can visit schools at a regular basis. However, awareness is only the first step to prevent diseases. The second step is to make sure that the knowledge leads to the right hygienic behavior and here soap can play a major role.

"Our MMH activities in India started in 2015 in close collaboration with local stakeholders. That's why we co- create with others, build kindergarten buildings and train kindergarten teachers on health awareness in the rural villages, provide toilets in schools and contribute actively to a hygiene campaign of one of our social entrepreneurs in our network. A two year health awareness program for tribal people including various health topics and digital trainings as well as safety trainings for daily life are also part of our activities. With teaching people skills and enabling them to create their own income we do a next step. We run regularly leadership weeks for our managers in our project area, close to Coimbatore - and we learn a lot: because understanding and talking to the local communities and organizations is important to develop solutions that are meeting the real needs and which are accepted," says Manuela Pastore, global lead of Making More Health.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...